Cargando…

Intravitreal Fluocinolone Acetonide (ILUVIEN) Implant for the Treatment of Refractory Cystoid Macular Oedema After Retinal Detachment Repair

Cystoid macular oedema (CMO) is one of the most frequent postoperative macular complications to cause partial visual recovery after successful retinal detachment (RD) repair. Refractory CMO is difficult to treat and many strategies have been employed with varying degrees of success. We report for th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alfaqawi, Fadi, Sarmad, Ambreen, Ayesh, Kholoud, Mitra, Arijit, Sharma, Ash
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Galenos Publishing 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032957/ https://www.ncbi.nlm.nih.gov/pubmed/29988755 http://dx.doi.org/10.4274/tjo.34966

Ejemplares similares

Intravitreal fluocinolone acetonide implant (ILUVIEN®) for diabetic macular oedema: a literature review
por: Massa, Horace, et al.
Publicado: (2018)

Clinical Effectiveness of Intravitreal Fluocinolone Acetonide (FAc) (ILUVIEN™) in Patients with Diabetic Macular Oedema (DMO) Refractory to Prior Therapy: The Manchester Experience
por: Young, James F., et al.
Publicado: (2019)

Electronic Patient Records to Identify Patients in the United Kingdom with Diabetic Macular Oedema Suitable for ILUVIEN(®) (Fluocinolone Acetonide)
por: Butt, Farhat, et al.
Publicado: (2016)

Intravitreal Fluocinolone Acetonide Implant (FAc, 0.19 mg, ILUVIEN®) in the Treatment of Patients with Recurrent Cystoid Macular Edema After Pars Plana Vitrectomy
por: Lima-Fontes, Mário, et al.
Publicado: (2022)

Iluvien™ (Fluocinolone Acetonide 0.19 mg Intravitreal Implant) in the Treatment of Diabetic Macular Edema: A Review
por: Fusi-Rubiano, William, et al.
Publicado: (2018)

Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years
por: Fusi-Rubiano, William, et al.
Publicado: (2018)

Report of 12-months efficacy and safety of intravitreal fluocinolone acetonide implant for the treatment of chronic diabetic macular oedema: a real-world result in the United Kingdom
por: Alfaqawi, F, et al.
Publicado: (2017)

Correction to: Iluvien™ (Fluocinolone Acetonide 0.19 mg Intravitreal Implant) in the Treatment of Diabetic Macular Edema: A Review
por: Fusi-Rubiano, William, et al.
Publicado: (2020)

Intravitreal Fluocinolone Acetonide Implant (ILUVIEN(®)) for the Treatment of Retinal Conditions. A Review of Clinical Studies
por: Mushtaq, Yusuf, et al.
Publicado: (2023)

Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies
por: Pochopien, Michal, et al.
Publicado: (2019)

Clinical efficacy and safety of intravitreal fluocinolone acetonide implant for the treatment of chronic diabetic macular oedema: five-year real-world results
por: Dobler, Emilie, et al.
Publicado: (2022)

Anterior migration of intravitreal fluocinolone acetonide (Iluvien®) implant in a pseudophakic eye with intact posterior capsule
por: Alzaabi, Manal, et al.
Publicado: (2020)

Clinical utility of intravitreal fluocinolone acetonide (Iluvien(®)) implant in the management of patients with chronic diabetic macular edema: a review of the current literature
por: Saedon, Habiba, et al.
Publicado: (2017)

Changes in intraocular pressure after intravitreal fluocinolone acetonide (ILUVIEN): real-world experience in three European countries
por: Chakravarthy, Usha, et al.
Publicado: (2019)

Case Series Investigating the Efficacy and Safety of Bilateral Fluocinolone Acetonide (ILUVIEN(®)) in Patients with Diabetic Macular Edema
por: Elaraoud, Ibrahim, et al.
Publicado: (2016)

Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants
por: Yang, Y, et al.
Publicado: (2015)

Real-world experience with 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom
por: Bailey, C, et al.
Publicado: (2017)

Safety and effectiveness of the fluocinolone acetonide intravitreal implant (ILUVIEN): 3-year results from the European IRISS registry study
por: Khoramnia, Ramin, et al.
Publicado: (2023)

Fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema
por: Messenger, Wyatt B, et al.
Publicado: (2013)

Real-World Cost Savings Demonstrated by Switching Patients with Refractory Diabetic Macular Edema to Intravitreal Fluocinolone Acetonide (Iluvien): A Retrospective Cost Analysis Study
por: Ch’ng, Soon W., et al.
Publicado: (2017)

Long-term management of non-ischemic central retinal vein occlusion with fluocinolone acetonide intravitreal implant 190 μg (ILUVIEN®)
por: Coelho, João, et al.
Publicado: (2019)

Clinical impact of the 0.2 µg/day fluocinolone acetonide intravitreal implant: outcomes from the ILUVIEN(®) clinical evidence study in Portugal
por: Carneiro, Angela, et al.
Publicado: (2020)

A Novel Technique for Repositioning of a Migrated ILUVIEN(®) (Fluocinolone Acetonide) Implant into the Anterior Chamber
por: El-Ghrably, Ibraheem A., et al.
Publicado: (2015)

Efficacy of 0.2 μg/day fluocinolone acetonide implant (ILUVIEN) in eyes with diabetic macular edema and prior vitrectomy
por: Meireles, A, et al.
Publicado: (2017)

Intravitreal dexamethasone implant for the treatment of cystoid macular oedema associated with acute retinal necrosis
por: Majumder, Parthopratim Dutta, et al.
Publicado: (2016)

Intravitreal fluocinolone acetonide 0.19 mg (ILUVIEN®) in patients with non-infectious uveitis: real-world effectiveness and safety outcomes at 12 months
por: Moll-Udina, Aina, et al.
Publicado: (2023)

A novel intravitreal fluocinolone acetonide implant (Iluvien(®)) in the treatment of patients with chronic diabetic macular edema that is insufficiently responsive to other medical treatment options: a case series
por: Schmit-Eilenberger, Vera K
Publicado: (2015)

Fluocinolone acetonide (0.19 mg) intravitreal implant reduces treatment burden and improves practice resource utilisation for patients with diabetic macular oedema
por: Byun, Matthew, et al.
Publicado: (2020)

Challenging Clinical Cases – A Walk Through Supplemental Therapy with Intravitreal Ranibizumab Therapy Following Treatment of Diabetic Macular Edema with the 0.19 mg Fluocinolone Acetonide Implant (ILUVIEN(®))
por: Pessoa, Bernardete, et al.
Publicado: (2020)

Fluocinolone Acetonide 0.19 mg Implant in Patients with Cystoid Macular Edema Due To Irvine–Gass Syndrome
por: Marques, João Heitor, et al.
Publicado: (2021)

Visual function and retinal morphological changes after single suprachoroidal delivery of fluocinolone acetonide (Iluvien®) implant in eyes with chronic diabetic macular edema
por: El Rayes, Ehab N., et al.
Publicado: (2023)

Intravitreal vs. subtenon triamcinolone acetonide for the treatment of diabetic cystoid macular edema
por: Cellini, Mauro, et al.
Publicado: (2008)

Evaluation of 0.2 µg/day fluocinolone acetonide (ILUVIEN) implant in a cohort of previously treated patients with diabetic macular oedema (DMO): a 36-month follow-up clinical case series
por: Ahmed, Muna, et al.
Publicado: (2020)

Preventing relapse in non-infectious uveitis affecting the posterior segment of the eye – evaluating the 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN(®))
por: Bodaghi, Bahram, et al.
Publicado: (2020)

Management of Patients with Diabetic Macular Edema Switched from Dexamethasone Intravitreal Implant to Fluocinolone Acetonide Intravitreal Implant
por: Baillif, Stéphanie, et al.
Publicado: (2022)

Case Series Investigating the Efficacy and Safety of Bilateral Fluocinolone Acetonide (ILUVIEN(®)) in Patients with Diabetic Macular Edema: 10 Eyes with 12 Months Follow-up
por: Elaraoud, Ibrahim, et al.
Publicado: (2016)

Clinical-Decision Criteria to Identify Recurrent Diabetic Macular Edema Patients Suitable for Fluocinolone Acetonide Implant Therapy (ILUVIEN(®)) and Follow-Up Considerations/Recommendations
por: Adán, Alfredo, et al.
Publicado: (2020)

Intravitreal Fluocinolone Acetonide for Diabetic Macular Edema: Long-Term Effect and Structure/Function Correlation
por: Minnella, Angelo Maria, et al.
Publicado: (2022)

Intravitreal Fluocinolone Acetonide May Decelerate Diabetic Retinal Neurodegeneration
por: Lynch, Stephanie K., et al.
Publicado: (2019)

Two-year interim safety results of the 0.2 µg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study
por: Mansour, Sam E, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ivcdiuuf8tiejvh2o04cs59hbc